Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis

Genome Research

Volumn 9, Issue 3, 1999, Pages 226-233

  Watson, J E Vivienne ^a   Gabra, Hani ^a   Taylor, Karen J ^a   Rabiasz, Genevieve J ^a   Morrison, Harris ^a   Perry, Paul ^a   Smyth, John F ^a   Porteous, David J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ARTICLE; ASCITES; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FIBROBLAST; GENE MAPPING; HOMOZYGOTE; HUMAN; HUMAN CELL; OVARY CANCER; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUPPRESSOR GENE; TECHNIQUE; TUMOR CELL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

FALLOPIA;

EID: 0032922456     PISSN: 10889051     EISSN: None     Source Type: Journal    
DOI: 10.1101/gr.9.3.226     Document Type: Article

References (48)

1. Bast, R.C., C.M. Boyer, I. Jacobs, F.J. Xu, S. Wu, J. Wiener, M. Kohler, and A. Berchuck. 1993. Cell-growth regulation in epithelial ovarian-cancer. Cancer 71: 1597-1601.
2. Black, D., J. Watson, and A. Hurlestone. 1998. Tumour suppressor genes and cellular senescence in ovarian cancer. In Ovarian cancer 5 (ed. F. Sharp, P. Mason, T. Blackett, and J. Berek), pp. 49-66. Chapman and Hall, London, UK.
3. Bouzyk, M., S. Bryant, C. Evans, S. Guioli, S. Ford, K. Schmidt, P. Goodfellow, S. Povey, M. Rebello, S. Rousseaux et al. 1997. Integrated radiation hybrid and yeast artificial chromosome map of chromosome 9p. Eur. J. Hum. Genet. 5: 299-307.
4. Cairns, P., T.J. Polascik, Y. Eby, K. Tokino, J. Califano, A. Merlo, L. Mao, J. Herath, R. Jenkins, W. Westra et al. 1995. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11: 210-212.
5. Caldas, C., S.A. Hahn, LT. da Costa, M.S. Redston, M. Schutte, A.B. Seymour, C.L. Weinstein, R.H. Hruban, C.J. Yeo, and S.E. Kern. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32.
6. Campbell, I.G., G. Beynon, M. Davis, and P. Englefield. 1995. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer 63: 222-225.
7. Chang, J., J. Bridgewater, M. Gore, C. Fisher, J. Schofield, R. A'hern, B. Ponder, I. Jocobs, M. McKeage, and L. Kelland et al. 1994. Non-surgical aspects of ovarian cancer. Lancet 343: 335-341.
8. Chenevix-Trench, G., J. Kerr, M. Friedlander, T. Hurst, B. Sanderson, M. Coglan, B. Ward, J. Leary, and S.K. Khoo. 1994. Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am. J. Hum. Genet. 55: 143-149.
9. Chenevix-Trench, G., J. Kerr, T. Hurst, Y.C. Shih, D. Purdie, L. Bergman, M. Friedlander, B. Sanderson, A. Zournazi, and T. Coombs et al. 1997. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. Genes Chromosomes Cancer 18: 75-83.
10. Chuaqui, R.F., Z. Zhuang, and M.J. Merino. 1997. Molecular genetic events in the development and progression of ovarian cancer in humans. Mol. Med. Today 3: 207-213.
11. Hamilton, T.C., R.C. Young, W.M. McKoy, K.R. Grotzinger, J.A. Green, E.W. Chu, J. Whang-Peng, A.M. Rogan, W.R. Green, and R.F. Ozols. 1983. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389.
12. Herman, J.G., A. Merlo, L. Mao, R.G. Lapidus, J.P. Issa, N.E. Davidson, D. Sidransky, and S.B. Baylin. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 4525-4530.
13. Ichikawa, Y., S. Yoshida, Y. Koyama, M. Hirai, T. Ishikawa, M. Nishida, H. Tsunoda, T. Kubo, M. Miwa, and K. Uchida. 1996. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int. J. Cancer 69: 466-470.
14. Iwabuchi, H., M. Sakamoto, H. Sakunaga, Y.Y. Ma, M.L. Carcangiu, D. Pinkel, T.L. Yang-Feng, and J.W. Gray. 1995. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res. 55: 6172-6180.
15. Kallioniemi, O.P., A. Kallioniemi, J. Piper, J. Isola, F.M. Waldman, J.W. Gray, and D. Pinkel. 1994. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231-243.
16. Kamb, A., N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S.V. Tavtigian, E. Stockert, R.R. Day, B.E. Johnson, and M.H. Skolnick 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
17. Langdon, S., S. Lawrie, F. Hay, M. Hawkes, A. McDonald, I. Hayward, D. Schol, J. Hilgers, R. Leonard, and J. Smyth. 1988. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 48: 6166-6172.
18. Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, and R. McCombie et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
19. Lisitsyn, N. and M. Wigler. 1995. Representational difference analysis in detection of genetic lesions in cancer. Methods Enzymol. 254: 291-304.
20. Lisitsyn, N., N. Lisitsyn, and M. Wigler. 1993. Cloning the differences between two complex genomes. Science 259: 946-951.
21. Mandai, M., I. Konishi, T. Komatsu, T. Mori, S. Arao, H. Nomura, Y. Kanda, H. Hiai, and M. Fukumoto. 1995. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: Correlation with tumour progression and nm23 gene expression. Br. J. Cancer 72: 691-695.
22. Merajver, S.D., T.M. Pham, R.F. Caduff, M. Chen, E.L. Poy, K.A. Cooney, B.L. Weber, F.S. Collins, C. Johnston, and T.S. Frank. 1995. Somatic mutations in the BRCA1 gene in sporadi ovarian tumours. Nat. Genet. 9: 439-443.
23. Merlo, A., J.G. Herman, L. Mao, D.J. Lee, E. Gabrielson, P.C. Burger, S.B. Baylin, and D. Sidransky. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686-692.
24. Nobori, T., K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
25. Ohta, M., H. Inoue, M. Cotticelli, K. Kastury, R. Baffa, J. Palazzo, Z. Siprashvili, M. Mori, P. McCue, and T. Druck et al. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597.
26. Piper, J., D. Rutovitz, D. Sudar, A. Kallioniemi, O.P. Kallioniemi, F.M. Waldman, J.W. Gray, and D. Pinkel. 1995. Computer image analysis of comparative genomic hybridization. Cytometry 19: 10-26.
27. Provencher, D.M., C.L. Finstad, P.E. Saigo, S.C. Rubin, W.J. Hoskins, M.G. Federici, E. Stockert, K.O. Lloyd, and J. Lewis, Jr. 1993. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol. Oncol. 50: 78-83.
28. Puig, S., A. Ruiz, C. Lazaro, T. Castel, M. Lynch, J. Palou, A. Vilalta, J. Weissenbach, J.M. Mascaro, and X. Estivill. 1995. Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene. Am. J. Hum. Genet. 57: 395-402.
29. Risinger, J.I., A. Berchuck, M.F. Kohler, and J. Boyd. 1994. Mutations of the E-cadherin gene in human gynecologic cancers. Nat. Genet. 7: 98-102.
30. Rodabaugh, K.J., R.B. Biggs, J.A. Qureshi, A.J. Barrett, W.R. Welch, D.A. Bell, R.S. Berkowitz, and S.C. Mok. 1995. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11: 1249-1254.
31. Schultz, D.C., L. Vanderveer, K.H. Buetow, M.P. Boente, R.F. Ozols, T.C. Hamilton, and A.K. Godwin. 1995. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 55: 2150-2157.
32. Schutte, M., L.T. da-Costa, S.A. Hahn, C. Moskaluk, A.T. Hoque, E. Rozenblum, C.L. Weinstein, M. Bittner, P.S. Meltzer, and J.M. Trent et al. 1995. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Prof. Natl. Acad. Sci. 92: 5950-5954.
33. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
34. Shih, Y.C., J. Kerr, J. Liu, T. Hurst, S.K. Khoo, B. Ward, B. Wainwright, and G. Chenevix-Trench. 1997. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int. J. Cancer 70: 508-511.
35. Slamon, D.J., W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, and A. Ullrich. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
36. Steck, P.A., M.A. Pershouse, S.A. Jasser, W.K. Yung, H. Lin, A.H. Ligon, L.A. Langford, M.L. Baumgard, T. Hattier, and T. Davis et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.
37. Steel, C.and H. Gabra. 1997. Oncogenes and tumour suppressor genes in ovarian cancer. In Biology of female cancers (ed. S. Langdon, W. Miller, and A. Berchuck), pp. 133-152. CRC Press LLC, New York, NY.
38. Takahashi, H., K. Behbakht, P.E. McGovern, H.-S. Chiu, F.J. Couch, B.L. Weber, L.S. Friedman, M.-C. King, M. Furusato, and V.A. LiVolsi et al. 1995. Mutation analysis of BRCA1 gene in ovarian cancers. Cancer Res. 55: 2998-3002.
39. Takahashi, H., H.C. Chiu, C.A. Bandera, K. Behbakht, P.C. Liu, F.J. Couch, B.L. Weber, V.A. LiVolsi, M. Furusato, and B.A. Rebane et al. 1996. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 56: 2738-2741.
40. Tapper, J., R. Butzow, T. Wahlstrom, M. Seppala, and S. Knuutila. 1997. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br. J. Cancer 75: 1782-1787.
41. Teneriello, M.G., M. Ebina, R.I. Linnoila, M. Henry, J.D. Nash, R.C. Park, and M.J. Birrer. 1993. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53: 3103-3108.
42. Walker, G.J., J.F. Flores, J.M. Glendening, A. Lin, I.D.C. Markl, and J.W. Fountain. 1998. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22: 157-163.
43. Weaver-Feldhaus, J., N.A. Gruis, S. Neuhausen, D. Le Paslier, E. Stockert, M.H. Skolnick, and A. Kamb. 1994. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. Natl. Acad. Sci. 91: 7563-7567.
44. Williamson, M.P., P.A. Elder, M.E. Shaw, J. Devlin, and M.A. Knowles. 1995. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet. 4: 1569-1577.
45. Wolf, C., I. Hayward, S. Lawrie, K. Buckton, M. McIntyre, D. Adams, A. Lewis, A. Scott, and J. Smyth. 1987. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer 39: 695-702.
46. Wolff, E., T. Liehr, U. Vorderwulbecke, A.H. Tulusan, E.M. Husselein, E. Gebhart. 1997. Frequent gains and losses of specific chromosome segments in human ovarian carcinomas shown by comparative genomic hybridization. Int. J. Oncol. 11: 19-23.
47. Wooster, R., G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, and G. Micklem. 1995. Identification of the breast cancer susceptibility gene BRCA2. [published erratum appears in Nature 379: 749, 1996.] Nature 378: 789-792.
48. Yokota, J., Y. Tsunetsugu-Yokota, H. Battifora, C. Le Fevre, and M.J. Cline. 1986. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 261-265.